Doug Melton

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more

ViaCyte-CyT49-PSC

ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the …

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more Read More »

ViaCyte & CRISPR Therapeutics team up to battle diabetes

ViaCyte

What happens when one of the most exciting stem cell biotechs ViaCyte teams up with a firm like CRISPR Therapeutics to use a combination of gene editing and cell therapy? Hopefully a synergistic partnership emerges that in this case can develop an effective stem cell-based therapy for diabetes. You can see a press release on …

ViaCyte & CRISPR Therapeutics team up to battle diabetes Read More »

Movers & Shakers in Stem Cell & Regenerative Medicine Field

stem-cell-movers-and-shakers

Stem Cell & Regenerative Medicine field researchers move around to different places fairly often. It is interesting to note trends and also see who received what kinds of awards and such. Below is a list of some recent movers and shakers. George Daley got the ISSCR Public Service Award (you can see other ISSCR Awards here). …

Movers & Shakers in Stem Cell & Regenerative Medicine Field Read More »

ViaCyte on the Rise: First Diabetes Trial Data & Acquires BetaLogics IP

VC-01-post-implant-final1-e1503703572933

Clinical research on Type I Diabetes is one of the most exciting and promising areas of stem cells and regenerative medicine for human disease. Two of the coolest companies out there in this arena have been ViaCyte and BetaLogics (owned by J&J). For more on ViaCyte see my interview with President and CEO Paul Laikind …

ViaCyte on the Rise: First Diabetes Trial Data & Acquires BetaLogics IP Read More »

Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc

Katarina-Le-Blanc

The path to the clinic is a slow and arduous activity, frustrating not only to the researcher and patient, but investors and biotech companies. Successful clinical translation of technologies requires a balance of science, streamlined translation and funding. To develop fantastic science and then realise the most important components cannot be adapted to the clinical …

Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc Read More »

New biotech Semma Therapeutics stem cell diabetes arena

Semma_05-4065

A new biotech startup, Semma Therapeutics, announced that it seeks to fight diabetes via translating technology from the lab of Doug Melton at Harvard to the clinic. Update: Note that the firm was recently acquired by Vertex. Another major player in cell therapy-based arena for Diabetes is most likely good news for patients. Quoted in the Boston …

New biotech Semma Therapeutics stem cell diabetes arena Read More »

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future

VC-01-post-implant-final1-e1503703572933

It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on …

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future Read More »

The Betatrophin Blues after Harvard Diabetes pub

Betatrophin

All the recent high-profile papers that are having troubles are bumming me out, with the latest example being the “Betatrophin” Diabetes paper from Harvard last year. Yesterday it was called into major doubt by a new Cell paper from a group led by Jesper Gromada at Regeneron. The authors of the original 2013 Betatrophin paper–Doug Melton’s team at Harvard– indicated …

The Betatrophin Blues after Harvard Diabetes pub Read More »

Takeaways From Harvard Stem Cells for Diabetes Paper

Harvard-stem-cells-Diabetes

The idea of using stem cells for treat Type I Diabetes is very promising and could have huge practical impact. Real progress has been achieved toward this goal over the last decade. In perhaps another decade there might be a validated treatment. A new stem cell paper has just come out in Cell from Harvard in this …

Takeaways From Harvard Stem Cells for Diabetes Paper Read More »

Stem cell journal club: dishing on Nature paper on making iPS cells inside mice

What if you could reprogram cells inside of an organism to a different fate and, for instance, make IPS cells? We can, right? But when most of us think about making induced pluripotent stem (iPS) cells, we imagine it all happening in a little plastic dish in our labs or in our colleague’s labs, not …

Stem cell journal club: dishing on Nature paper on making iPS cells inside mice Read More »